

Supplemental Digital Content 2. Change From Baseline to Week 48 in Biomarkers of Inflammation and Atherogenesis in the Pooled SWORD-1 and SWORD-2 Studies

	Dolutegravir + rilpivirine Day 1 to Week 48			CAR Day 1 to Week 48		
	n ^a	Mean (SD)	Median (IQR)	n ^a	Mean (SD)	Median (IQR)
C-reactive protein, mg/L						
Baseline	512	2.81 (4.56)	1.30 (0.60, 2.75)	504	2.77 (4.42)	1.30 (0.60, 2.70)
Change from Baseline at Week 48	480	0.11 (5.38)	0.00 (-0.60, 0.70)	481	0.47 (6.96)	0.00 (-0.50, 0.90)
Difference (<i>P</i> value) ^b					-0.10 (0.1431)	
Soluble CD14, ng/mL						
Baseline	510	1703.31 (511.68)	1677.46 (1369.23, 1999.04)	501	1699.31 (490.36)	1697.63 (1386.49, 1977.52)
Change from Baseline at Week 48	479	419.09 (686.18)	363.72 (-41.43, 849.12)	478	779.87 (773.67)	774.09 (338.82, 1185.67)
Difference (<i>P</i> value) ^b					-374.42 (<0.0001)	
Interleukin-6, ng/L						
Baseline	512	2.19 (1.78)	1.61 (1.13, 2.58)	502	2.24 (2.49)	1.57 (1.07, 2.64)
Change from Baseline at Week 48	478	0.04 (2.56)	-0.04 (-0.76, 0.61)	479	-0.11 (2.85)	-0.04 (-0.65, 0.60)
Difference (<i>P</i> value) ^b					-0.01 (0.8653)	
Soluble CD163, µg/L						
Baseline	509	590.48 (229.74)	537.70 (435.60, 697.70)	500	601.26 (235.64)	555.10 (446.05, 700.95)
Change from Baseline at Week 48	477	57.99 (184.72)	52.80 (-31.50, 139.20)	476	54.18 (227.68)	26.05 (-44.40, 134.05)
Difference (<i>P</i> value) ^b					14.90 (0.1165)	
D-dimer, nmol/L FEU^a						
Baseline	504	1.87 (2.89)	1.15 (1.04, 1.72)	495	1.80 (2.55)	1.10 (1.04, 1.64)
Change from Baseline at Week 48	463	-0.01 (2.18)	0.00 (-0.05, 0.38)	465	-0.05 (2.72)	0.00 (-0.11, 0.27)
Difference (<i>P</i> value) ^b					0.00 (0.1967)	
FABP-2, ng/mL						
Baseline	512	2.97 (2.50)	2.25 (1.41, 3.75)	500	2.93 (2.17)	2.37 (1.38, 3.91)
Change from Baseline at Week 48	478	-2.13 (2.38)	-1.46 (-2.61, -0.67)	477	-1.47 (1.89)	-1.03 (-2.02, -0.34)
Difference (<i>P</i> value) ^b					-0.47 (<0.0001)	
sVCAM-1, µg/L						
Baseline	512	1933.50 (524.83)	1894.63 (1557.74, 2265.11)	502	1958.64 (567.84)	1871.93 (1580.96, 2242.29)
Change from Baseline at Week 48	479	-2.43 (990.05)	-21.45	479	63.17 (983.17)	14.28

Week 48

(-412.14, 341.55)

(-385.03, 432.08)

Difference (*P* value)^b

-52.44 (0.2113)

CAR, current antiretroviral therapy; FABP-2, fatty acid binding protein-2; FEU, fibrinogen-equivalent units; sVCAM-1, soluble vascular cell adhesion molecule-1. ^aRepresents the number of participants who had samples collected at both Baseline and Week 48. ^bHodges-Lehmann median difference (dolutegravir + rilpivirine group – CAR group) and Wilcoxon rank sum test *P* values.⁹